Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating

Maxim Group analyst Jason McCarthy maintained a Buy rating on Kairos Pharma, Ltd. yesterday and set a price target of $4.00.

Jason McCarthy has given his Buy rating due to a combination of factors, primarily focusing on the promising developments in Kairos Pharma’s clinical trials. The company’s ongoing Phase 2 study of ENV-105 combined with Erleada in metastatic castration-resistant prostate cancer (mCRPC) patients has shown encouraging results, with a median progression-free survival exceeding 13 months, which is significantly above the current benchmarks. This suggests that ENV-105 may effectively re-sensitize tumors to standard-of-care therapies, presenting a substantial opportunity in the treatment landscape.
Additionally, the Phase 1 trial of ENV-105 with Tagrisso in EGFR-mutated non-small cell lung cancer (NSCLC) is expected to yield initial data by the end of the year. This trial targets a critical area of unmet need, as resistance to anti-EGFR drugs is a common challenge in this patient population. The potential for ENV-105 to overcome this resistance could provide significant upside if the results are positive. These clinical advancements, coupled with a strategic focus on addressing drug resistance in cancer treatment, underpin McCarthy’s optimistic outlook and Buy recommendation for Kairos Pharma.